Fig. 2: Combinational TCP and GSK-J1 treatment synergistically induces prominent cell apoptosis and senescence in vitro. | British Journal of Cancer

Fig. 2: Combinational TCP and GSK-J1 treatment synergistically induces prominent cell apoptosis and senescence in vitro.

From: Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1

Fig. 2

a Percentages of apoptotic cells in Cal27 and FaDu cells following treatment with TCP and GSK-J1 alone or in combination (48 h) were measured by Annexin V/PI assay. b The protein levels of these apoptotic markers after treatments as indicated were determined by western blot. The concentrations of TCP and GSK-J1 are 0.8 and 0.75 mM, 20 and 15 μM in Cal27 and FaDu, respectively. c SA-β-gal staining (left panel) and percentages of senescent cells (right quantitative bar graph) were measured by senescence β-galactosidase cell-staining assay after 48 h of drug treatment. d The protein levels of these senescence-related markers after treatments as indicated were measured by western blot. The concentrations of TCP and GSK-J1 are 0.5 and 0.25 mM, 12.5 and 5 μM in Cal27 and FaDu, respectively. Data shown here are mean ± SD from three independent experiments, *P < 0.05, **P < 0.01, ANOVA analyses with Tukey's multiple comparisons test.

Back to article page